SOURCE: MedEvoke


August 21, 2014 09:29 ET

MedEvoke Selected for the Inc. 500|5000 List of Fastest-Growing Privately Held Companies

HIGH BRIDGE, NJ--(Marketwired - Aug 21, 2014) - MedEvoke, a Medisys Health Communications Company, and a premier provider of strategically aligned scientific narrative development for the biopharmaceutical industry, today announced their selection to the Inc. 500|5000 list, an exclusive ranking of the nation's fastest-growing privately held companies. With three-year revenue growth of approximately 200%, MedEvoke has tripled the number of clients since 2010, including at least one major new client every year. MedEvoke additionally ranked an impressive 4th among healthcare suppliers in New Jersey. 

Anna Walz, CEO of MedEvoke noted, "We are very pleased to have achieved this milestone. In this industry, it is very challenging to realize significant growth, but MedEvoke has tapped into a significant need in the biopharmaceutical industry -- achieving global alignment in the development of singular evidence-based scientific narratives. MedEvoke's expertise and proprietary ISIS methodology have helped dozens of biopharmaceutical companies reconcile their competing strategies and objectives. We believe this has been fundamental in driving our success over the past five years." 

According to recent estimates, the biopharmaceutical industry typically spends $4-6B annually on extraneous or unnecessary clinical endpoints. Achieving global alignment leads to more efficient, powerful trial design and the potential for stronger product labels. This is critical when considering the fact that only about 10% of products in development ultimately launch, and 90% of those launched products already have a competitor in late stage development.

MedEvoke currently supports most of the top 20 pharmaceutical companies, as well as numerous mid-size and emerging biotechnology companies. The company now shares a pedigree with other Inc. 500|5000 awardees including Microsoft, Timberland, Vizio, Intuit, Chobani, Oracle, and

About MedEvoke

MedEvoke is a premier provider of globally aligned, evidence-based scientific narrative development for the biopharmaceutical industry. Leveraging its proven expertise and a simple, yet powerful methodology, MedEvoke ensures organizational alignment by reconciling a client's competing goals, objectives, languages, cultures and budgets across the many operational functions and regional affiliates. MedEvoke's approach mitigates the risks associated with duplicated effort, unclear direction and poor communications, allowing clients to gain a competitive advantage, even when faced with unexpected changes in personnel, clinical trial results, or competitive environment. Headquartered in High Bridge, NJ, MedEvoke holds certifications from WBENC, NMSDC, and SBA.

Contact Information

  • Contact:
    John Walz
    Chief Financial Officer
    Phone: 908.638.5885